Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
Open Access
- 1 September 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 15 (9), 1295-1301
- https://doi.org/10.1002/ibd.20927
Abstract
Background. Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX tThis publication has 15 references indexed in Scilit:
- Efficacy of Biologicals in the Treatment of Rheumatoid ArthritisPharmacology, 2008
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseaseGastrointestinal Endoscopy, 2006
- Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgeryGut, 2005
- Long-Term Evolution of Disease Behavior of Crohn's DiseaseInflammatory Bowel Diseases, 2002
- Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the diseaseGut, 2001
- Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprineGastrointestinal Endoscopy, 1999
- Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.Gastroenterology, 1997
- Clinical, biological, and endoscopic picture of attacks of Crohn's diseaseGastroenterology, 1990
- Methotrexate Induces Clinical and Histologic Remission in Patients with Refractory Inflammatory Bowel DiseaseAnnals of Internal Medicine, 1989